Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 68001-540

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 68001-540). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Bortezomib 01)

Chemical structure of Bortezomib, the active ingredient in the injectable lyophilized powder formulation. The diagram shows its molecular framework with characteristic functional groups and ring systems relevant to its chemical identity.*

FDA Label Image

Figure 1 (Bortezomib 02)

A Kaplan-Meier survival curve chart showing the percentage of patients over time (in months) comparing two treatment groups: Vc-MP (red solid line) and MP (blue dashed line). The y-axis represents the percentage of patients, and the x-axis indicates time in months up to 24. Below the graph is a table listing the number of patients at risk at various time points for both groups. The chart includes a p-value indicating statistical comparison between the groups.*

FDA Label Image

Figure 2 (Bortezomib 03)

A Kaplan-Meier survival curve depicting the percentage of patients over time in months, comparing two groups labeled Vc-MP and MP. The chart shows patient survival declining over approximately 72 months, with Vc-MP consistently showing a higher percentage of patients than MP. A table beneath the graph indicates the number of patients at risk at various time points for both groups, and a p-value less than 0.05 is noted from a log-rank test.*

FDA Label Image

Figure 3 (Bortezomib 04)

A Kaplan-Meier survival curve comparing two patient groups treated with Bortezomib and Dexamethasone over time in days. The Y-axis shows the proportion of patients, and the X-axis represents time up to approximately 450 days. The graph illustrates higher patient survival proportion for Bortezomib compared to Dexamethasone, with sample sizes and statistical significance indicated.*

FDA Label Image

Figure 4 (Bortezomib 05)

A Kaplan-Meier survival curve illustrating the proportion of patients over time (days) for two treatment groups: Bortezomib and Dexamethasone. The graph shows patient counts at various timepoints and includes a p-value indicating statistical comparison. The Bortezomib group maintains a higher proportion of patients over the study period compared to the Dexamethasone group.*

FDA Label Image

Figure 5 (Bortezomib 06)

A survival curve chart comparing two treatment groups, VcR-CAP and R-CHOP, over a period of 0 to 60 months. The y-axis represents the percentage of patients, and the x-axis shows time in months. The VcR-CAP group shows a higher survival percentage than the R-CHOP group over time. The chart includes the number of subjects at risk at various time points for both groups and a log-rank test p-value of less than 0.001.*

FDA Label Image

Figure 6 (Bortezomib 07)

A survival curve graph showing the percentage of subjects alive over months from randomization for two treatment groups: VcR-CAP (solid line) and R-CHOP (dashed line). The x-axis represents time in months up to 108, and the y-axis shows percentage of subjects alive from 0 to 100%. The graph includes a table of subjects at risk per group over time and reports a hazard ratio with 95% confidence interval.*

FDA Label Image

Vial Label (Bortezomib 08)

Bortezomib 3.5 mg/Vial injection powder for solution label by BluePoint Laboratories. The label indicates it is a single-dose vial for intravenous or subcutaneous use, with storage instructions and a caution indicating cytotoxicity.*

FDA Label Image

Carton Label (Bortezomib 09)

Packaging label for Bortezomib for Injection, 3.5 mg per vial, a lyophilized powder for solution by BluePoint Laboratories. The label includes dosing and reconstitution instructions for intravenous and subcutaneous use, storage conditions, and a warning that the drug is a cytotoxic agent. It also displays NDC 68001-540-36, a barcode, and manufacturer details including Qilu Pharmaceutical (Hainan) Co., Ltd.*

FDA Label Image

Inside Flap (Bortezomib 10)

Packaging label layout for Bortezomib injection powder, lyophilized, for solution by BluePoint Laboratories. The label features a reconstitution information section with instructions for subcutaneous and intravenous injections. It specifies using 0.9% sodium chloride to reconstitute the powder to concentrations of 2.5 mg/mL for subcutaneous and 1 mg/mL for intravenous use. The label uses Pantone colors 072 C (blue), 485 C (red), 106 C (yellow), and black.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.